Discovery and Optimization of Small-Molecule Ligands for V-domain Ig Suppressor of T-cell Activation (VISTA).

V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint that affects the ability of T-cells to attack tumors. A FRET-based high throughput screening identified NSC622608 as the first small-molecule ligand for VISTA. Investigation of the interaction of NSC622608 with VISTA using STD NMR and molecular modeling enabled the identification of a potential binding site in VISTA for NSC622608. Screening NSC622608 against a library of single-point VISTA mutants revealed the key residues in VISTA interacting with NSC622608. Further structural optimization resulted in a lead with submicromolar VISTA binding affinity. The lead compound blocked VISTA signaling in vitro, enhanced T-cell proliferation, and restored T-cell activation in the presence of VISTA-expressing cancer cell lines. This work would enable future development of small molecules targeting VISTA as immunomodulators and imaging probes.

[1]  Lieping Chen,et al.  Structural insight into T cell coinhibition by PD-1H (VISTA) , 2020, Proceedings of the National Academy of Sciences.

[2]  A. Yamniuk,et al.  VISTA is an acidic pH-selective ligand for PSGL-1 , 2019, Nature.

[3]  Po-Ssu Huang,et al.  Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation. , 2019, Cell reports.

[4]  J. D'haese,et al.  Advances in cancer immunotherapy 2019 – latest trends , 2019, Journal of Experimental & Clinical Cancer Research.

[5]  T. Holak,et al.  CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? , 2019, bioRxiv.

[6]  Lukás Jendele,et al.  PrankWeb: a web server for ligand binding site prediction and visualization , 2019, Nucleic Acids Res..

[7]  C. Iacobuzio-Donahue,et al.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[8]  Jun Yu Li,et al.  VSIG‐3 as a ligand of VISTA inhibits human T‐cell function , 2018, Immunology.

[9]  Longqin Hu,et al.  Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules , 2018, Medicinal research reviews.

[10]  J. Chisholm,et al.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves , 2019, The Journal of Immunology.

[11]  N. Matsumura,et al.  VISTA expressed in tumour cells regulates T cell function , 2018, British Journal of Cancer.

[12]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[13]  Hongming Zhang,et al.  Current status and future directions of cancer immunotherapy , 2018, Journal of Cancer.

[14]  S. Malarkannan,et al.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation , 2018, Cellular & Molecular Immunology.

[15]  G. De Velasco,et al.  Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials , 2018, Oncotarget.

[16]  J. Wilmott,et al.  Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients , 2017, Modern Pathology.

[17]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[18]  J. Pin,et al.  BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues , 2012, Front. Endocrin..

[19]  Lieping Chen,et al.  Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models , 2011, The Journal of Immunology.

[20]  David C. Gondek,et al.  VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.

[21]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.